美国乳腺癌幸存者中治疗相关胸部软组织肉瘤:一项回顾性队列研究
该回顾性队列研究基于Kaiser Permanente(KP)队列(15 940例)和SEER 13注册队列(457 300例),评估美国乳腺癌幸存者发生胸部软组织肉瘤的潜在协同因素。结果显示放疗是两个队列中最强的危险因素,KP队列RR 8.1(95% CI 1.1-60.4),SEER队列RR 3.0(95% CI 2.4-3.8);糖尿病和高血压是与血管肉瘤相关的新发现,作者认为值得进一步研究作为预防和监测的潜在靶点。
要点
- 放疗是胸部软组织肉瘤最强危险因素,KP队列RR 8.1,SEER队列RR 3.0。
- KP队列中94.7%(18/19)胸部软组织肉瘤发生于接受放疗的女性。
- 高血压和糖尿病各与约5倍血管肉瘤风险相关,作者认为值得进一步研究。
核心结论
- 放疗是两个队列中胸部软组织肉瘤的最强危险因素。
- 糖尿病和高血压作为血管肉瘤潜在危险因素的新发现,作者认为值得进一步研究作为预防策略和加强监测的潜在靶点。
研究设计与样本
- 回顾性队列研究,数据来源于美国Kaiser Permanente(KP)队列和SEER 13注册队列。
- KP队列纳入1990年1月1日至2016年12月31日在KP Colorado、KP Northwest(服务俄勒冈州和华盛顿州西南部)或KP Washington诊断为乳腺癌的15 940例女性,含详细治疗数据和合并症(包括乳腺癌诊断时或之前的髙血压和糖尿病)电子病历数据。
- SEER队列纳入1992年1月1日至2016年12月31日在美国13个SEER注册中心诊断为乳腺癌的457 300例女性,含初始治疗数据(有 vs 无或未知)。
- 两队列纳入标准为诊断为I-III期乳腺癌、年龄20-84岁、接受乳腺癌手术、且乳腺癌诊断后存活至少1年的女性乳腺癌幸存者。
- 结局为乳腺癌诊断后至少1年发生的任何第二原发胸部软组织肉瘤(血管肉瘤和其他亚型);采用多变量Poisson回归模型评估危险因素。
主要发现
- KP队列中位随访9.3年(IQR 5.7-13.9),15 940例可评估女性中19例(0.1%)发生胸部软组织肉瘤(11例血管肉瘤,8例其他亚型)。
- KP队列中94.7%(18/19)胸部软组织肉瘤发生于接受放疗的女性,放疗与胸部软组织肉瘤风险显著增加相关(RR 8.1 [95% CI 1.1-60.4];p=0.0052),但与处方剂量、分割或加量无关。
- KP队列中蒽环类药物后血管肉瘤的RR为3.6(95% CI 1.0-13.3;p=0.058);烷化剂与其他肉瘤风险增加相关(RR 7.7 [95% CI 1.2-150.8];p=0.026)。
- KP队列中高血压史(RR 4.8 [95% CI 1.3-17.6];p=0.017)和糖尿病(RR 5.3 [95% CI 1.4-20.8];p=0.036)各与约5倍血管肉瘤风险增加相关。
- SEER队列中位随访8.3年(IQR 4.3-13.9),457 300例患者中430例(0.1%)发生后续胸部软组织肉瘤(268例血管肉瘤,162例其他亚型);77.9%(335/430)发生于放疗后,放疗与胸部软组织肉瘤风险显著增加相关(RR 3.0 [95% CI 2.4-3.8];p<0.0001);血管肉瘤中,保乳手术加放疗 vs 乳房切除加放疗的RR为1.9(95% CI 1.1-3.3;p=0.012)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者在解释中引用糖尿病和高血压作为血管肉瘤潜在危险因素的新发现,并指出其值得进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Soft tissue sarcoma is a rare but serious side-effect of radiotherapy to treat breast cancer, and rates are increasing in the USA. We evaluated potential co-factors in two complimentary cohorts of US breast cancer survivors. METHODS: In this retrospective cohort study, we sourced data from the Kaiser Permanente (KP) cohort and the Surveillance, Epidemiology, and End Results (SEER) 13 registries cohort, both in the USA. The KP cohort included 15 940 women diagnosed with breast cancer from Jan 1, 1990, to Dec 31, 2016, in KP Colorado, KP Northwest (which serves Oregon and Southwest Washington state), or KP Washington, with detailed treatment data and comorbidities (including hypertension and diabetes at or before breast cancer diagnosis) from electronic medical records. The SEER cohort included 457 300 women diagnosed with breast cancer from Jan 1, 1992, to Dec 31, 2016, within the 13 SEER registries across the USA, with initial treatment data (yes vs no or unknown). Eligibility criteria in both cohorts were female breast cancer survivors (stage I-III) aged 20-84 years at diagnosis who had breast cancer surgery, and had survived at least 1 year after breast cancer diagnosis. The outcome of interest was any second thoracic soft tissue sarcoma (angiosarcomas and other subtypes) that developed at least 1 year after breast cancer diagnosis. Risk factors for thoracic soft tissue sarcoma were assessed using multivariable Poisson regression models. FINDINGS: In the KP cohort, median follow-up was 9·3 years (IQR 5·7-13·9) and 19 (0·1%) of 15 940 eligible, evaluable women developed a thoracic soft tissue sarcoma (11 angiosarcomas, eight other subtypes). Most (94·7%; 18 of 19) thoracic soft tissue sarcomas occurred in women treated with radiotherapy; thus, radiotherapy was associated with a significantly increased risk of developing a thoracic soft tissue sarcoma (relative risk [RR] 8·1 [95% CI 1·1-60·4]; p=0·0052), but there was no association with prescribed dose, fractionation, or boost. The RR of angiosarcoma after anthracyclines was 3·6 (95% CI 1·0-13·3; p=0·058). Alkylating agents were associated with an increased risk of developing other sarcomas (RR 7·7 [95% CI 1·2-150·8]; p=0·026). History of hypertension (RR 4·8 [95% CI 1·3-17·6]; p=0·017) and diabetes (5·3 [1·4-20·8]; p=0·036) were each associated with around a five-times increased risk of angiosarcoma. In the SEER cohort, 430 (0·1%) of 457 300 patients had subsequent thoracic soft tissue sarcomas (268 angiosarcomas and 162 other subtypes) after a median follow-up of 8·3 years (IQR 4·3-13·9). Most (77·9%; 335 of 430) cases occurred after radiotherapy; thus, radiotherapy was associated with a significantly increased risk of developing a thoracic soft tissue sarcoma (RR 3·0 [95% CI 2·4-3·8]; p<0·0001) and, for angiosarcomas, the RR for breast-conserving surgery plus radiotherapy versus mastectomy plus radiotherapy was 1·9 (1·1-3·3; p=0·012). By 10 years after radiotherapy, the cumulative incidence of thoracic soft tissue sarcoma was 0·21% (95% CI 0·12-0·34) in the KP cohort and 0·15% (95% CI 0·13-0·17) in SEER. INTERPRETATION: Radiotherapy was the strongest risk factor for thoracic soft tissue sarcoma in both cohorts. This finding, along with the novel findings for diabetes and hypertension as potential risk factors for angiosarcomas, warrant further investigation as potential targets for prevention strategies and increased surveillance. FUNDING: US National Cancer Institute and National Institutes of Health.
引用
- Veiga LHS, Vo JB, Curtis RE, et al. Treatment-related thoracic soft tissue sarcomas in US breast cancer survivors: a retrospective cohort study. Lancet Oncol. 2022. PMID: 36240805. doi:10.1016/S1470-2045(22)00561-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。